Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. Adding cabozantinib to nivolumab-ipilimumab delays disease progression in previously untreated advanced
    RCC patients with intermediate/poor IMDC risk

2. Sotorasib demonstrates superior PFS versus docetaxel in patients with pre-treated KRAS.G12C-mutated
    NSCLC

3. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term
    efficacy and quality of life analyses

4. Adding atezolizumab to standard platinum-based chemotherapy plus bevacizumab does not improve PFS
    in patients with late relapsing ovarian cancer

5. Durvalumab plus tremelimumab effective for patients with progressive, refractory advanced thyroid
    carcinoma